Clinical Trial Update: Nicorandil Study to Reduce Cardiac Death After Percutaneous Coronary Intervention (PCI) in Hemodialysis Patients [NA]

View source ↗

Summary

A completed clinical trial assessing nicorandil to reduce cardiac death after PCI in hemodialysis patients, sponsored by Toujinkai Hospital.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Heart Failure
• Myocardial Infarction

Drugs mentioned

• Nicorandil (nicorandil)

Snippet

Sponsor: Toujinkai Hospital | Conditions: Acute Myocardial Infarction, Congestive Heart Failure | NA | Status: COMPLETED